Active — Not RecruitingNot Applicable

Procedure for Duodenum to Ileal Diversion to Treat Type 2 Diabetes

Argentina15 participantsStarted 2019-09-23

Plain-language summary

Study will monitor changes in HbA1c for subjects in Intervention arm vs control arm.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. T2DM diagnosis ≥6 months but \< 10 years
✓. On 1 or more oral diabetes medications (with one at the minimum recommended therapeutic dose)
✓. Hemoglobin A1C (HbA1c) between and including 6.5 and 10.0% (58 mmol/mol to 86 mmol/mol) at time of enrollment and has had a stable HbA1c over a 3-month period (i.e., \<0.3% reduction)
✓. Stable medication regimen (i.e., no change in diabetes medications) for at least 3 months prior to Screening Visit.

Mean change in HbA1c

Timeframe: 12 months

NCT IDNCT03130244

SponsorGI Windows, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-15